Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides
CM MAcLEOD, RG Hodges… - The Journal of …, 1945 - ncbi.nlm.nih.gov
CM MAcLEOD, RG Hodges, M Heidelberger, WG Bernhard
The Journal of experimental medicine, 1945•ncbi.nlm.nih.govImmunization of man with 0.03 to 0.06 mg. of each of the capsular polysaccharides of
pneumococcus types I, II, V, and VII, given in a single subcutaneous injection, has been
shown to be effective in preventing pneumonia caused by these types but not that due to
heterologous types. 2. Immunity appears within a period of 2 weeks following injection of the
polysaccharides. Its duration was not determined, although 6 months can be set as a
minimum. 3. Immunization of alternate subjects in the population reduced greatly the …
pneumococcus types I, II, V, and VII, given in a single subcutaneous injection, has been
shown to be effective in preventing pneumonia caused by these types but not that due to
heterologous types. 2. Immunity appears within a period of 2 weeks following injection of the
polysaccharides. Its duration was not determined, although 6 months can be set as a
minimum. 3. Immunization of alternate subjects in the population reduced greatly the …
Abstract
1. Immunization of man with 0.03 to 0.06 mg. of each of the capsular polysaccharides of pneumococcus types I, II, V, and VII, given in a single subcutaneous injection, has been shown to be effective in preventing pneumonia caused by these types but not that due to heterologous types. 2. Immunity appears within a period of 2 weeks following injection of the polysaccharides. Its duration was not determined, although 6 months can be set as a minimum. 3. Immunization of alternate subjects in the population reduced greatly the incidence of pneumonia in the non-immunized. 4. The carrier rate for pneumococcus types I, II, V, and VII was lowered significantly in the immunized group as compared with the controls. It is suggested that an over-all reduction in the incidence of carriers was responsible for the lowered rates for pneumococcal pneumonia in the non-immunized group.
ncbi.nlm.nih.gov